Novel combination therapy shows promise for advanced neuroendocrine tumors A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.
https://www.news-medical.net/n....ews/20251021/Novel-c